Serum Institute gets DCGI nod for trials of Oxford's COVID-1
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Serum Institute of India (SII) has been granted permission by Drugs Controller of General of India (DCGI) to conduct Phase 2, 3 human trials of Oxford-AstraZeneca coronavirus vaccine in India, a government official has said.

The vaccine will be called Covishield in India. Serum Institute is already preparing to produce 20 crore -- 200 million -- doses of COVISHIELD (SII-ChAdOx1nCov-19).

The nod was given after it was asked by an expert committee to resubmit a revised protocol of carrying the clinical trials of the vaccine.

SII has partnered with AstraZeneca which has got the license of manufacturing Oxford's vaccine.

After a thorough evaluation, the DCGI has given approval to SII to perform phase 2, 3 clinical trials based on the recommendation of the Subject Expert Committee (SEC).

Serum Institute CEO Adar Poonawalla said Oxford-AstraZeneca coronavirus vaccine will be branded as Covishield and they are hopeful that it will be an efficacious, immunogenic vaccine, viable for mass use.

Poonawalla said they hope to launch it by the end of 2020 and by first quarter Covishield will start reaching masses.

Source: https://www.indiatvnews.com/news/good-news/serum-institute-oxford-astrazeneca-coronavirus-vaccine-india-human-trials-sii-gets-dcgi-permission-639131
Dr. T●●●●z H●●●●●●i and 6 others like this3 shares
Like
Comment
Share